Published: 15 January 2020
Author(s): Antonio Brucato, Francesco Cianci, Carla Carnovale
Issue: January 2020

There is consensus on starting urate-lowering therapy (ULT) in cases of symptomatic hyperuricemia, but the frequent condition of asymptomatic hyperuricemia (AH), remains a challenge, given the different findings of studies on the relationship between serum acid uric levels and comorbidities. Here we systematically assess randomized controlled trials (RCTs) evaluating ULT in patients with AH. We also discuss the safety profile of ULT and provide an overview of recent recommendations from current guidelines.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.